NFKB1 and breast carcinoma: Given the potential for improved efficacy and greater tolerability of CFZ and CFZ's known down-regulation of nuclear factor κB (NF-κB) signaling, we investigated the antitumor activity of CFZ in a panel of molecularly unique breast cancer cell lines alone or in combination with DOX.